Clinical trial
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
NCT00088608 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00088608 |
|---|---|
| Title | A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease |
| Official title | A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cushing's Syndrome |
| Intervention type | Drug |
| Interventions | SOM230 s.c. |
| Enrollment | 26 |
| Start date | Apr 1, 2004 |
| Primary completion | Jun 1, 2006 |
| First posted | Aug 2, 2004 |
| Last update posted | Nov 7, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: